PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT2797855

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
BRUCE SELIGMANN	12/21/2011
BJ KERNS	01/10/2012
JOHN LUECKE	12/19/2011
MATT ROUNSEVILLE	01/05/2012
IHAB BOTROS	12/21/2011
MARK SCHWARTZ	12/21/2011

RECEIVING PARTY DATA

Name:	HTG MOLECULAR DIAGNOSTICS, INC.	
Street Address:	3430 E. GLOBAL LOOP	
City:	TUCSON	
State/Country:	ARIZONA	
Postal Code:	85706	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	14130397

CORRESPONDENCE DATA

Fax Number: (503)595-5301

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via

US Mail.

Phone: 503-595-5300

Email: susan.graf@klarquist.com

Correspondent Name: SUSAN W. GRAF, KLARQUIST SPARKMAN, LLP

Address Line 1: 121 SW SALMON STREET

Address Line 2: SUITE 1600

Address Line 4: PORTLAND, OREGON 97204

ATTORNEY DOCKET NUMBER:	8736-87469-06
NAME OF SUBMITTER:	SUSAN W. GRAF, PH.D.
SIGNATURE:	/Susan W. Graf/
DATE SIGNED:	04/02/2014

Total Attachments: 4

502751259 REEL: 032587 FRAME: 0541

PATENT



PATENT REEL: 032587 FRAME: 0542

ASSIGNMENT

We, Bruce Seligmann, of Tucson, Arizona, BJ Kerns, of Tucson, Arizona, John Luecke, of Tucson, Arizona, Matt Rounseville, of Tucson, Arizona, Ihab Botros, of Tucson, Arizona, and Mark Schwartz, of Tucson, Arizona, have invented METHODS OF DETECTING GENE FUSIONS for which the following patent applications have been filed:

U.S. Provisional Patent Application No. 61/504,040, filed on July 1, 2011; and PCT Patent Application No. PCT/US2011/063803, filed on December 7, 2011 which are herein referred to as "the Patent Applications."

The invention was made as a result of our activities at or on behalf of HTG Molecular Diagnostics, Inc., or as a result of our utilization of information, facilities or other resources of HTG Molecular Diagnostics, Inc. The conditions under which said invention was made are such as to entitle HTG Molecular Diagnostics, Inc. to the entire right, title, and interest in the invention and the patent application in the United States and its territories and dependencies, and all other countries of the world.

In consideration of our obligations and other valuable consideration, we the undersigned hereby sell, assign, and transfer to HTG Molecular Diagnostics, Inc., its successors and assigns, our full and exclusive right, title, and interest in the invention and the Patent Applications throughout the United States of America and its territories and dependencies, and all other countries of the world. This includes an assignment of all non-provisional patent applications and any Letters Patent that may be granted on the invention for corresponding non-provisional patent applications in the United States of America and all countries throughout the world, and any divisional, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof; and the right to claim priority from the Patent Applications as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law.

We authorize and request the issuance of said Letters Patent to HTG Molecular Diagnostics, Inc. as assignee of the entire right, title, and interest to be held as fully and entirely as the same would have been held by us had this assignment not been made.

We warrant that there are no outstanding assignments, grants, liens, encumbrances, or agreements either written, oral, or implied that will impair, diminish, limit, or abridge the interest herein conveyed at the time of the execution of the present assignment.

We also agree upon reasonable request to communicate to HTG Molecular Diagnostics, Inc., its representatives, successors, assigns, or agents, any facts known to us respecting the invention(s), and testify in any legal proceedings, sign all lawful papers, execute all non-provisional, divisional, continuing, and reissue applications, make all rightful oaths, provide all requested documents, and do everything reasonably possible to aid HTG Molecular Diagnostics, Inc., its representatives, successors, assigns, or agents to obtain and enforce proper patent protection for the invention(s) in the United States or any foreign country. These provisions are binding upon our heirs, legal representatives, administrators and assigns.

In testimony whereof, the Assignors have signed their names on the dates indicated.

Dated; /7_	(21/1/	w.	
		- Harris Commission	X ,
		Bruce Seligmann	
Witnessed by:	Smalin	Share II a	
Print Name:	Sondra	Shaeller	
Date:	12/21/	<u>.//.</u>	

Dated: 10 (2	Lylen BJ Kerns
Witnessed by: Kella Mark Print Name: Kella Mark Date: \(\alpha - (0 - \frac{20}{2}) \)	
Dated: 13/19/2011	JA JA 72/ /9/ 2/1/
Witnessed by: <u>Fells Hub</u> Print Name: <u>Kells Thole</u> Date: <u>12-(9-201)</u>	
Dated: 1340 05, 2312	Mattt Rounseville
Witnessed by: <u>Jandra Jha</u> Print Name: <u>Sandra Shaef</u> Date: 1-5-2013	<u>H</u>

Dated: 12/21/11 = 56/BS
Ihab Botros
Witnessed by: $\frac{300000000000000000000000000000000000$
Dated: 12-21-2011
Mark Schwartz
Witnessed by: <u>Something</u>
Print Name: <u>Sandra Shaeffor</u> Date: /2-2/-20//